Human clinical results reported in the Internt'l Journal of Oncology reveal 83% of patients with chemo-resistant metastatic pancreatic cancer tumors who received Rexin-G, a new gene therapy, showed impressive tumor reduction or tumor death!
In a second study, 64% tumor response was observed in patients with metastatic breast cancer as well as colon cancer, uterine cancer, muscle and vocal cord cancers, as well as malignant melanoma. In a third study, where optimally adjusted doses of Rexin-G were administered to three patients, tumor reduction and/or necrosis was achieved in all three patients.
The dramatic functionality of this, the world's first cancer targeted gene delivery system is profound. The treatment appears to offer broad spectrum activity in many treatment-resistant tumor types, and, equally important, the treatment appears to be exceptionally safe and easily tolerated by patients.
Lack of toxicity, dramatic tumor reduction, and the enhanced quality-of-life experienced by patients receiving Rexin-G during Phase I/II FDA approved trials, constitute meaningful clinical benefits that underscore the need for expediting development and testing of Rexin-G for pancreatic cancer patients, and, potentially, for all solid tumor patients. The FDA has already taken note of these first human test results and has moved to speed the process of testing and marketing.
Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, helped develop the remarkable mew treatment said, "Whereas logistics had previously stymied delivery of genetic medicine to target lesions (tumors) within the body, intravenous infusions of Rexin-G (succeeded and) has stymied intractable cancers without collateral damage to normal organs."
The results compiled in these pioneering early studies, already have convinced the U.S. FDA to grant Rexin-G "orphan drug" status for treatment of pancreatic cancer, and subsequently, to provide federal support to speed up and continue clinical trials using Rexin-G in the United States. Other countires aren't waiting:
Based on the dramatic new results, the Philippine Bureau of Food and Drugs aren't waiting. They already have granted Rexin-G approval for use in treating all chemo-resistant tumor types in the Phillipines.
In a second study, 64% tumor response was observed in patients with metastatic breast cancer as well as colon cancer, uterine cancer, muscle and vocal cord cancers, as well as malignant melanoma. In a third study, where optimally adjusted doses of Rexin-G were administered to three patients, tumor reduction and/or necrosis was achieved in all three patients.
The dramatic functionality of this, the world's first cancer targeted gene delivery system is profound. The treatment appears to offer broad spectrum activity in many treatment-resistant tumor types, and, equally important, the treatment appears to be exceptionally safe and easily tolerated by patients.
Lack of toxicity, dramatic tumor reduction, and the enhanced quality-of-life experienced by patients receiving Rexin-G during Phase I/II FDA approved trials, constitute meaningful clinical benefits that underscore the need for expediting development and testing of Rexin-G for pancreatic cancer patients, and, potentially, for all solid tumor patients. The FDA has already taken note of these first human test results and has moved to speed the process of testing and marketing.
Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, helped develop the remarkable mew treatment said, "Whereas logistics had previously stymied delivery of genetic medicine to target lesions (tumors) within the body, intravenous infusions of Rexin-G (succeeded and) has stymied intractable cancers without collateral damage to normal organs."
The results compiled in these pioneering early studies, already have convinced the U.S. FDA to grant Rexin-G "orphan drug" status for treatment of pancreatic cancer, and subsequently, to provide federal support to speed up and continue clinical trials using Rexin-G in the United States. Other countires aren't waiting:
Based on the dramatic new results, the Philippine Bureau of Food and Drugs aren't waiting. They already have granted Rexin-G approval for use in treating all chemo-resistant tumor types in the Phillipines.
